AXLRx · by MoatRx
The commercial consulting engine for pharma.
Bring the commercial question for any drug, market or buyer. The engine builds the answer as a consulting deliverable, and every figure in it carries a live source.
319 published analyses22 live connectors5 markets in the library72h to deliverable
Public sources the engine reads live
- PubMedliterature
- ClinicalTrials.govtrials
- FDAregulator
- EMAregulator
- WHOepidemiology
- SEC EDGARfilings
- CMS Coveragecoverage
- DrugBanktargets
- ChEMBLtargets
- Open Targetstargets
- bioRxivliterature
- ICD-10coverage
Names shown for reference. No affiliation with, or endorsement by, any source is implied.
Recalled vs verified
Your AI recalls. AXLRx verifies.
A language model answers from what it remembers. The engine opens the source before it answers, and drops what it cannot find.
Illustrative. The widely quoted framing, recalled rather than retrieved: no source, and out of date.
- Opened the current FDA label for Wegovy
- Checked ESSENCE,
PMID 40305708 - Checked Rezdiffra approval,
NDA217785
From the US MASH Competitive Intelligence record · every figure traced · read the analysis
The engine
Your question in. A verified deliverable out.
The AXLRx engine reasons on the MoatRx method, retrieves from live primary sources and drops any figure it cannot find in the document it cites.
- Drug
- your asset
- Market
- any, worldwide
- Buyer
- who decides
- Decision
- the one on your desk
See it run
One question, run end to end.
US MASH competitive intelligence, from the run record. Click the tabs.
Who controls the US MASH market and how should Rezdiffra defend access against in-market semaglutide?
The US MASH market is a live two-drug duopoly: Rezdiffra (resmetirom, approved Mar 2024) and Wegovy (semaglutide 2.4 mg, approved Aug 2025) both hold accelerated approval for noncirrhotic F2-F3 MASH. Semaglutide is already in-market, not a 2027 entrant, so the defensible move is locking preferred payer access and the fibrosis-regression position now, in a Year 0-1 retention fight.
| Agent (company) | Class / MOA | US status | Pivotal trial |
|---|---|---|---|
| Rezdiffra (resmetirom) — Madrigal | Oral THR-β agonist | Approved Mar 14, 2024 (accelerated; NDA217785) | MAESTRO-NASH (NCT03900429) |
| Wegovy (semaglutide 2.4 mg) — Novo Nordisk | GLP-1 receptor agonist (injectable) | Approved Aug 15, 2025 (accelerated) | ESSENCE (NCT04822181) |
| Lanifibranor — Inventiva | Pan-PPAR (α/δ/γ) agonist | Phase 3 (pre-approval) | NATiV3 (NCT04849728) |
| Efruxifermin — Akero | FGF21 analog | Phase 3 (pre-approval) | SYNCHRONY Histology (NCT06215716) + cirrhosis (NCT06528314) |
- The duopoly is live: corrected competitive status
- Head-to-head clinical positioning
- US payer architecture & the access defense
- The IRA price-negotiation clock
- Pipeline & emerging white space
- The US diagnosis funnel & share-leakage levers
PDF brief · Excel model · PowerPoint readout
Modules
Four modules run on the engine today.
Each answers one named commercial question and ships as a working file.
Worked example
One question. Four modules. One deliverable.
Where does an oral therapy win in US MASH, with which clinicians, against which pipeline, and for how many patients?
- Competitive IntelligenceMaps who holds which cohort, and on what evidence
- KOL MappingTiers the clinicians who shape practice in the indication
- Clinical Trial AnalyticsLists the programmes closest to a readout, and their endpoints
- Patient FlowSizes the pool the label can reach, and where patients leak
- 01The duopoly is live: corrected competitive status
- 02Head-to-head clinical positioning
- 03US payer architecture & the access defense
- 04The IRA price-negotiation clock
- 05Pipeline & emerging white space
- 06The US diagnosis funnel & share-leakage levers
Section titles from the published US MASH analysis · open it
How it runs
Four steps. Scope in 24 hours, deliverable in 72.
- AskThe decision, the asset, the market and the buyer it is for.
- ScopeConfirmed with you within 24 hours. The module and the evidence base are fixed here.
- Run and verifyThe engine builds the analysis. Every figure passes the source gate, then a MoatRx consultant reads it.
- DeliverWithin 72 hours: PDF, Excel model and PowerPoint, with a readout call.
Library
Inspect the engine's output before you commission it.
319 analyses across 21 indications, each readable in full. Real deliverable pages sit beside them.
Built for
The teams that carry the commercial decision.
Insights
How the hard questions get answered.
commercial-planning
commercial-planningTalk to us
Twenty minutes with a consultant, before anything is commissioned.
Bring the decision in front of you. We tell you which module answers it, what the evidence base will be, and when you will have it. If the engine is the wrong tool, we say so.
- Your question, framed as the decision it serves
- Which module fits, or whether a scoped engagement does
- Scope, sources and delivery date, confirmed within 24 hours
Questions buyers ask
What is AXLRx?
AXLRx is a commercial consulting engine for pharma, built by MoatRx. It takes a commercial question about a drug, a market and a buyer, and returns a consulting deliverable in which every figure is traced to a live source. It runs as a commissioned service: there is no platform to operate.
How fast is an AXLRx report delivered?
Scope is confirmed within 24 hours of your request, and the deliverable arrives within 72 hours.
How does AXLRx verify its figures?
Each figure is cited to a PMID, trial ID or source URL at the point of writing, checked to appear in the cited document, and re-checked in an independent audit pass. A figure that fails is removed, not estimated. A MoatRx consultant reads every deliverable before it ships.
What types of report does AXLRx publish?
Four modules run on the engine: Competitive Intelligence, KOL Mapping, Clinical Trial Analytics and Patient Flow. The library also holds disease landscape, payer and HTA, launch readiness, pricing, market sizing and HTA strategy analyses, which are run as scoped engagements.
How do I commission a report?
Use the commission form, or book a 20-minute scoping call. You tell us the drug, the market, the buyer and the decision; we confirm scope within 24 hours.
What AI does the engine run on?
The engine's reasoning layer runs on a frontier language model, currently Anthropic's Claude, working to the MoatRx method. The model is never a source: every figure comes from a connected primary source such as PubMed, ClinicalTrials.gov, FDA or EMA, and is checked against that source before it is kept.
Which markets does AXLRx cover?
The library covers the US, UK, GCC, Germany and France. Other markets are scoped on request.
Bring us the question in front of you.
Scope confirmed in 24 hours. Delivered in 72.